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NoOBJECTIVES This study thoroughly explored the demographic and imaging characteristics, as well as the all-cause and
cause-speciﬁc mortality risks of patients with a coronary artery calcium (CAC) score $1,000 in the largest dataset of this
population to date.
BACKGROUND CAC is commonly used to quantify cardiovascular risk. Current guidelines classify a CAC score of >300
or 400 as the highest risk group, yet little is known about the potentially unique imaging characteristics and mortality
risk in individuals with a CAC score $1,000.
METHODS A total of 66,636 asymptomatic adults were included from the CAC consortium, a large retrospective
multicenter clinical cohort. Mean patient follow-up was 12.3  3.9 years for patients with cardiovascular disease (CVD),
coronary heart disease (CHD), cancer, and all-cause mortality. Multivariate Cox proportional hazards regression models
adjusted for age, sex, and conventional risk factors were used to assess the relative mortality hazard of individuals with
CAC $1,000 compared with, ﬁrst, a CAC reference of 0, and second, with patients with a CAC score of 400 to 999.
RESULTS There were 2,869 patients with CAC $1,000 (86.3% male, mean 66.3  9.7 years of age). Most patients with
CAC $1,000 had 4-vessel CAC (mean: 3.5  0.6 vessels) and had greater total CAC area, higher mean CAC density, and
more extracoronary calcium (79% with thoracic artery calcium, 46% with aortic valve calcium, and 21% with mitral valve
calcium) than those with CAC scores of 400 to 999. After full adjustment, those with CAC $1,000 had a 5.04- (95%
conﬁdence interval [CI]: 3.92 to 6.48), 6.79- (95% CI: 4.74 to 9.73), 1.55- (95% CI:1.23 to 1.95), and 2.89-fold (95% CI:
2.53 to 3.31) risk of CVD, CHD, cancer, and all-cause mortality, respectively, compared to those with CAC score of 0. The
CAC $1,000 group had a 1.71- (95% CI: 1.41 to 2.08), 1.84- (95% CI: 1.43 to 2.36), 1.36- (95% CI:1.07 to 1.73), and 1.51-
fold (95% CI: 1.33 to 1.70) increased risk of CVD, CHD, cancer, and all-cause mortality compared to those with CAC scores
400 to 999. Graphic analysis of CAC $1,000 patients revealed continued logarithmic increase in risk, with no clear
evidence of a risk plateau.
CONCLUSIONS Patients with extensive CAC (CAC $1,000) represent a unique very high-risk phenotype with mortality
outcomes commensurate with high-risk secondary prevention patients. Future guidelines should consider CAC $1,000
patients to be a distinct risk group who may beneﬁt from the most aggressive preventive therapy.
(J Am Coll Cardiol Img 2019;-:-–-) © 2019 by the American College of Cardiology Foundation.N 1936-878X/$36.00 https://doi.org/10.1016/j.jcmg.2019.02.005
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2C oronary artery calcium (CAC),determined by acquiring cardiac-gated noncontrast computed to-
mography imaging, is now routinely used to
quantify atherosclerotic burden in the coro-
nary arteries. Higher levels of CAC have
been strongly associated with an increased
risk of coronary heart disease (CHD) and all-
cause mortality (1). In fact, most studies
have found CAC to be a more robust predic-
tor of coronary events in the asymptomatic
primary prevention population than conven-tional risk scores such as the Framingham Risk Score
or the Pooled Cohort Equations (PCE) (2–4). CAC, as a
measurement of cumulative subclinical vascular
injury, also appears to be an independent predictor
of other important clinical outcomes such as stroke,
dementia, cancer, and chronic kidney disease (5–7).
Current guidelines classify persons with CAC
scores >300 or >400 at the highest risk group for
cardiovascular disease (CVD) events, with no further
differentiation above that threshold (8–11). To date,
few studies have explored the commonly encoun-
tered, extensively calciﬁed plaque phenotype of
persons with CAC scores $1,000. There are few data
for the demographic and imaging characteristics
of this population, and even fewer long-term data
for the relative risks of cause-speciﬁc mortality. For
example, it remains unclear if these patients consti-
tute a unique population with an extremely high CHD
risk or if the extensively calciﬁed nature of their
atherosclerosis puts them at high all-cause mortality
risk but no higher CHD risk than those with CAC >300
or >400. Prior studies investigating these extensive
Agatston scores have been limited by small sample
sizes and by studying only all-cause mortality (1,12).
Therefore, the present study sought to compre-
hensively describe the demographic characteristics,
the baseline cardiovascular risk factors, and the
computed tomography (CT) imaging features of this
unique and clinically important population, as well as
to determine the risks for long-term cause-speciﬁc
long-term mortality. To accomplish this, the CAC
Consortium, which is the largest cohort of patients
with measured CAC to date, was used (13).
umai Medical Center, Los Angeles, California; gDivision of Cardiolog
iovascular Imaging Department, Houston Methodist Hospital, H
enter for Outcomes Research and Evaluation, Yale University Sch
d by U.S. National Institutes of Health/National Heart Lung and
grant from General Electric. Dr. Nasir is a member of the advisory
ave no relationships relevant to the contents of this paper to dis
received October 26, 2018; revised manuscript received JanuaryMETHODS
STUDY DESIGN AND STUDY POPULATION. Analysis
involved 66,636 asymptomatic adults ($18 years of
age) without known CHD, from the multicenter CAC
Consortium study, which was designed to study the
relationship between clinical CAC scoring and long-
term cause-speciﬁc mortality. Details for data
collection, preparation, and harmonization were
published previously (13). In summary, this study
collected data from 1991 through 2010, and follow-
up data were collected until June 2014. Four medi-
cal centers with $10 years of experience scanning
CAC (according to CAC Consortium study site inclu-
sion criteria) from 3 different states (California,
Ohio, and Minnesota) contributed patient data to the
CAC Consortium. All CAC scans were clinically indi-
cated and physician-referred. All study participants
provided informed consent at the time of CAC
scanning. Institutional Review Board approval for
coordinating center activities was obtained at the
Johns Hopkins Hospital.
COMPUTED TOMOGRAPHY DATA. Each individual
study site performed routine noncontrast cardiac-
gated CT scans for the clinical determination of CAC
scores. A common standard protocol was used for
each scanner technology, and scans were read locally
at each center, using the Agatston method (13). Elec-
tron beam tomography was used for the CT scans
performed at most of the centers (93%), whereas 2
centers (7%), which had more recent CAC data, used
multidetector CT. It has been shown that electron
beam tomography has no clinically meaningful dif-
ferences compared with multidetector CT scanners in
assessing CAC scores (14).
In addition, data for the total number of vessels
with CAC (0 to 4) were available in 54,678 patients
(82%), thoracic aortic calcium (TAC) scores in 34,024
patients (51%), aortic valve calcium (AVC) scores in
10,007 patients (15%), mitral valve calcium (MVC)
scores in 10,008 patients (15%), and mean density (CT
attenuation) of calciﬁed coronary lesions in 20,052
patients (30%). In patients with CAC density data, a
summed area of all CAC lesions (in square millime-
ters) was determined by dividing the total Agatstony, Mount Sinai St. Luke’s Hospital, New York, New
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3CAC score by the mean density (in Hounsﬁeld
units [HU]) divided by 100 (to back-calculate the
mean density weighting factor in the Agatston
protocol) (15).
MEASUREMENT AND DEFINITION OF BASELINE
CHARACTERISTICS AND RISK FACTORS. Participants had
baseline characteristics, risk factors, and laboratory
data collected at the time of the CAC scan and/or as
part of their routine clinical visit. Data for race was
available from only a subset of the study population
(n ¼ 42,964 [64%]) (Supplemental Table 1). Hyper-
tension was deﬁned as current treatment with anti-
hypertensive medications or prior diagnosis of
hypertension. Dyslipidemia was deﬁned as prior
diagnosis of dyslipidemia (elevated triglycerides
and/or low high-density lipoprotein cholesterol
[HDL-C]), a prior diagnosis of hyperlipidemia, or
treatment with lipid-lowering medications. If
participants had concomitant laboratory data,
dyslipidemia was considered present if HDL-C
was <50 mg/dl in women and <40 mg/dl in
men, and low-density lipoprotein cholesterol
(LDL-C) was >160 mg/dl, or fasting triglycerides
were >150 mg/dl. Smoking status was deﬁned as
current cigarette smoker or not (yes/no). Diabetes was
deﬁned as prior diagnosis of diabetes or treatment
with antidiabetic drugs. At all centers except for the
Columbus, Ohio, site, family history of CHD was
determined by presence of a ﬁrst-degree relative with
history of CHD. The Columbus, Ohio, site used a more
stringent deﬁnition of family history of CHD, which
was <55 years of age in male relatives and <65 years of
age in female relatives. Multiple imputations were
conducted in the instance of partially missing risk
factor data (28% of cohort had at least 1 missing data
element). The imputation algorithm has been previ-
ously validated (13). The PCE were used to calculate
10-year risk of atherosclerotic cardiovascular disease
(ASCVD), as previously described (13).
ASCERTAINING OUTCOME. Mortality status was
determined by linking to the Social Security Admin-
istration Death Master File, using a previously vali-
dated algorithm (16). Individual-level causes of death
were ascertained by using International Classiﬁcation
of Disease-coded death certiﬁcates from the National
Death Index. Participants had follow-up data until
June 2014. Mean follow-up was 12.3  3.9 years.
STATISTICAL METHODS. CAC scores were divided
into CAC 0, CAC 1 to 399, CAC 400 to 999, and
CAC $1,000. Baseline characteristics were stratiﬁed
by CAC groups, reporting number (percentage) and
mean  SD as appropriate.Mortality rates (per 1,000 person-years) were
calculated for all-cause and cause-speciﬁc mortality.
For purposes of comparison, the proportion of a
particular cause-speciﬁc death was calculated as:
[(Ncause-speciﬁc deaths)/(Ntotal deaths)] for groups with
CAC scores 400 to 999 and $1,000.
Multivariate-adjusted Cox regression models were
used to assess the relative hazards of CAC groups for
cause-speciﬁc and all-cause mortality compared to
that of a reference group with Agatston score of 0.
Additionally, for the purposes of speciﬁc comparison,
the same models were used to assess risk of patients
with CAC $1,000 compared to a reference group of
CAC 400 to 999 (in the CAC $400 subset).
For the Cox regression models, an unadjusted
model (Model 1) and a fully adjusted model adjusted
for age, sex, and conventional cardiovascular risk
factors (Model 2) were chosen. We also included
Three other models were also included as supple-
mentary analyses (Supplemental Tables 2 and 3),
which were: 1) adjusted for age and sex (Model 3); 2)
Model 2 additionally was adjusted for race in the race
subset (Model 4); and 3) Model 2 was additionally
adjusted for study site (Model 5).
To graphically study risks around the CAC
threshold score of 1,000, cubic splines were used to
study the dose response relationship between CAC
score and mortality outcomes in a multivariate model
adjusted for age, sex, and conventional risk factors.
Knots were placed at CAC intervals of 100 (to capture
risk acceleration at low CAC scores) and CAC score of
1,000.
A 2-sided p value <0.05 was considered statisti-
cally signiﬁcant. All analyses were performed using
Stata version 14.0 software (Stata Corp., College Sta-
tion, Texas).
RESULTS
BASELINE CHARACTERISTICS. There were 2,869
patients (4.3% of the study cohort) with CAC
scores $1,000. These patients tended to be older (66.3
 9.7 years of age), more likely to be men (86.3%), and
were at higher risk (by number of risk factors, Fra-
mingham Risk Score and ASCVD risk score) than those
with lower CAC scores (Table 1). In the CAC $1,000
group, mean age was 66.3  9.7 years, and 27.4% were
younger than 60 years of age. In contrast, among
those with CAC scores of 400 to 999, 39.0% were
younger than 60 years of age.
Men comprised 55.5% of the CAC 0 group, 74.3% of
the CAC 1 to 399 group, 82.5% of the CAC 400 to 999
group, and 86.3% of the CAC $1,000 group.
TABLE 1 Baseline Characteristics According to Agatston Score Group
CAC 0
(n ¼ 29,757)
CAC 1 to 399
(n ¼ 29,601)
CAC 400 to 999
(n ¼ 4,409)
CAC $1,000
(n ¼ 2,869)
Age, yrs 49.9  9.2 56.5  9.8 63.0  9.4 66.3  9.7
<50 50.2 24.7 6.9 3.7
50-59 36.0 40.6 32.1 23.7
60-69 11.6 24.8 36.4 35.5
70-79 2.0 8.6 20.3 29.2
$80 0.2 1.2 4.3 7.9
Race (n ¼ 42,964)*
White 88.7 89.4 90.7 87.6
Asian 4.2 3.5 3.2 4.0
Black 2.2 2.3 1.5 3.1
Hispanic 3.2 3.0 2.8 3.4
Males 55.5 74.3 82.5 86.3
Hypertension 22.8 34.5 46.5 55.4
Smoking 8.9 10.1 11.0 10.2
Diabetes 3.9 7.5 12.8 19.4
Dyslipidemia 48.0 57.9 65.0 67.3
Family history of coronary
heart disease
45.6 46.3 46.5 48.5
Risk factors 1.3  0.9 1.5  0.9 1.8  0.9 1.9  0.9
0 21.7 14.6 10.2 7.7
1 39.0 34.5 28.1 23.7
2 29.2 33.6 36.4 36.4
>2 10.2 17.3 25.4 32.2
FRS, % score 7.8  5.9 12.4  9.0 18.0  12.3 21.8  15.0
<10 71.8 48.5 29.8 22.2
10-19 24.3 36.4 36.5 33.8
$20 3.8 15.1 33.6 44.0
ASCVD risk score† 3.8  4.7 8.6  8.7 15.1  12.0 20.2  14.9
<5 76.9 43.8 16.0 8.6
5-20 21.7 47.5 59.0 52.1
$20 1.4 8.7 25.0 39.2
Values are mean SD or n (%). *Data were available for only a subset of the study population. Detailed data for a
number of participants in each subgroup can be found in Supplemental Table 1. †Pooled cohort equations ASCVD
risk score.
ASCVD ¼ Atherosclerotic Cardiovascular Disease; CAC ¼ coronary artery calcium score; FRS¼ Framingham Risk
Score.
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4Generally, with increasing CAC score, the percentage
of participants with conventional cardiovascular risk
factors increased. The distribution of speciﬁc risk
factors is shown in Table 1.
Those with CAC scores $1,000 had a mean ASCVD
PCE risk score of 20.2  14.9%, in contrast to a mean
score of 15.1  12.0% for the CAC 400 to 999 group.
Although mean risk scores were high in the
CAC $1,000 group, the distribution (Table 1) indicates
that many scores were lower in the range where
clinical risk might have been considered uncertain
(ASCVD score: 5% to 20%).
IMAGING CHARACTERISTICS. In those with a CAC
score $1,000, most had 4-vessel CAC (52.4%)
(Table 2). Table 2 shows the distribution of imagingcharacteristics, including extracoronary artery cal-
cium by CAC group. The CAC $1,000 group tended to
have not only a higher total mean density but also a
substantially greater total CAC area than those with
lower CAC scores. Additionally, those with extensive
CAC $1,000 also tended to have more diffuse sys-
temic vascular disease than those with lower CAC
scores, with 79.3% having TAC, 45.7% having AVC,
and 21.4% having MVC.
ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY BY
CAC GROUP. Incidence rates of all outcomes
increased across all causes of mortality with
increasing CAC scores (Figure 1). Individuals with CAC
scores $1,000 had approximately twice the mortality
rate of those with CAC 400 to 999 across all causes of
mortality. For CVD mortality, the mortality rate per
1,000 person-years was 8.0 for those with CAC
scores $1,000 compared with 3.6 for those with CAC
scores of 400 to 999. Similarly for CHD mortality, the
mortality rate of the CAC $1,000 group was more than
twice that of the CAC 400 to 999 group (5.1 vs. 2.1,
respectively, per 1,000 person-years).
In those with CAC $1,000, the most common cause
of death was CVD (42.6%) followed by cancer (24.3%)
(Figure 2), whereas CVD death (36.5%) constituted a
smaller portion of all deaths in the CAC 400 to 999
score group, followed by cancer (28.0%).
MULTIVARIATE ADJUSTED HAZARD RATIOS.
Adjusted for conventional cardiovascular risk factors,
those with CAC $1,000 had a 5.04- (95% CI: 3.92 to
6.48), 6.79- (95% CI: 4.74 to 9.73), 1.55- (95% CI: 1.23
to 1.95), and 2.89-fold (95% CI: 2.53 to 3.31) risk of
CVD, CHD, cancer, and all-cause mortality, respec-
tively (Table 3, A. CAC 0 Reference Group), compared
to those with CAC¼0.
In a similarly adjusted model, those with CAC
scores $1,000 had a 1.71- (95% CI: 1.41 to 2.08), 1.84-
(95% CI: 1.43 to 2.36), 1.36- (95% CI: 1.07 to 1.73), and
1.51-fold (95% CI: 1.33 to 1.70) increase in CVD, CHD,
cancer, and all-cause mortality, respectively (Table 3,
B. CAC 400 to 999 Reference Group), compared to
those with CAC scores of 400 to 999.
The relationship between CAC score and multi-
variate adjusted risks of cause-speciﬁc and all-cause
mortality is displayed graphically in Figure 3.
Increasing CAC score above 1,000 led to higher hazard
ratios for all causes of mortality (Figure 3). Although
the hazard ratio increases with a slightly steeper slope
when the CAC score is <1,000, the hazard ratio con-
tinues to increase when CAC is $1,000, with no
apparent upper CAC threshold for this increase of
both cause-speciﬁc and all-cause mortality.
TABLE 2 Imaging Characteristics According to Agatston Score Group
Imaging Characteristics 1
CAC 0
(n ¼ 26,531)
CAC 1 to 399
(n ¼ 22,572)
CAC 400 to 999
(n ¼ 3,329)
CAC $1,000
(n ¼ 2,246)
Number of vessels with CAC 0  0 1.9  0.9 3.2  0.7 3.5  0.6
0 100.0 0.0 0.0 0.0
1 0.0 42.6 0.7 0.0
2 0.0 31.6 12.1 3.7
3 0.0 20.7 53.5 43.9
4 0.0 5.2 33.7 52.4
Imaging Characteristics 2
CAC 0
(n ¼ 16,250)
CAC 1 to 399
(n ¼ 14,214)
CAC 400 to 999
(n ¼ 2,147)
CAC $1,000
(n ¼ 1,413)
TAC 11.7 39.1 67.3 79.3
TAC 1-399 10.7 30.9 39.4 33.1
TAC 400-999 0.6 4.7 12.4 15.1
TAC $1,000 0.4 3.6 15.6 31.1
Imaging Characteristics 3
CAC 0
(n ¼ 4,842)
CAC 1 to 399
(n ¼ 3,842)
CAC 400 to 999
(n ¼ 739)
CAC $1,000
(n ¼ 584)
AVC 4.1 16.6 39.5 45.7
AVC 1-399 3.7 15.4 32.6 36.8
AVC 400-999 0.2 0.5 3.5 6.2
AVC $1,000 0.1 0.7 3.4 2.7
Imaging Characteristics 4
CAC 0
(n ¼ 4,842)
CAC 1 to 399
(n ¼ 3,843)
CAC 400 to 999
(n ¼ 739)
CAC $1,000
(n ¼ 584)
MVC 1.4 6.6 19.4 21.4
MVC 1-399 1.2 4.9 13.7 14.4
MVC 400-999 0.2 1.0 3.2 2.4
MVC $1,000 0.0 0.7 2.4 4.6
Imaging Characteristics 5
CAC 0
(n ¼ 9,678)
CAC 1 to 399
(n ¼ 8,575)
CAC 400 to 999
(n ¼ 1,159)
CAC $1,000
(n ¼ 640)
Estimated total area, mm2 0  0 37.5  41.9 254.1  70.3 691.6  365.8
Total mean density, HU 0  0 201.5  45.7 251.9  35.1 272.7  34.8
130-199 0.0 53.0 2.9 0.2
200-299 0.0 43.7 88.1 79.5
300-399 0.0 3.3 9.0 20.2
$400 0.0 0.1 0.0 0.2
Values are mean  SD or %.
AVC ¼ aortic valve calcium; MVC ¼ mitral valve calcium; TAC ¼ thoracic artery calcium; other abbreviations as
in Table 1.
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5DISCUSSION
This study provides the most extensive description of
individuals with extreme CAC scores (CAC $1,000) to
date. Findings show those with CAC scores $1,000
have both a higher area and density of calciﬁcation,
a more dispersed pattern of calciﬁcation in their
coronary artery tree (most had 4-vessel disease), with
a markedly more diffuse distribution of extracoronary
calciﬁcation than the other CAC groups. Additionally,
this study found that extreme CAC scores ($1,000)
are associated with a substantially increased risk of
CVD, CHD, cancer, and all-cause mortality, and
importantly, those with CAC scores $1,000 are at an
almost 2-fold higher risk of CVD mortality than those
with CAC scores of 400 to 999 (Central Illustration).
Although the mortality risk levels off slightly after the
CAC score reaches 1,000, risk still increases with no
apparent upper CAC threshold for both all-cause and
cause-speciﬁc mortality.
The few prior smaller studies of CAC patients with
scores $1,000 explored only all-cause rather than
cause-speciﬁc mortality or investigated individual
coronary endpoints rather than mortality outcomes
(1,12). For example, Patel et al. (1) showed that,
among 1,593 patients with extensive Agatston scores,
increasing CAC led to decreased survival, with
continued increased mortality risk past CAC those
with scores >2,000 (1). Other prior studies have
suggested that, although extensive CAC scores may
be associated with higher angina, they are not
associated with harder CHD events (12). For example,
in the MESA (Multi-Ethnic Study of Atherosclerosis;
NCT00005487) study, Coylewright et al. (12) found
that, in those with extensive CAC scores, $1,000
(n ¼ 257), there was no greater risk of CHD death or
myocardial infarction than in those with high CAC
scores (n ¼ 420 in the CAC 400 to 999 group). That
ﬁnding has been interpreted as being consistent with
the notion that a denser plaque phenotype may be no
riskier than lower CAC scores and could perhaps be
protective.
Indeed, with increasing recognition from other
imaging modalities, that denser calciﬁed plaque may
be more stable, and many have cast doubt on the
exceptional risk of extensive CAC scores (CAC
score $1,000). For example, a seminal paper by Criqui
et al. (17) found that, although higher CAC volume led
to increased CHD and CVD risk, higher CAC density
was actually signiﬁcantly protective against CHD and
CVD risk when CAC volume was kept constant. The
protective effect of high-density plaque makes sensebecause calciﬁed plaque is more stable than low
attenuation plaque (predominantly noncalciﬁed) in
prior studies using intravascular ultrasonography and
CTA (18–21). Because the CAC score is a combination
of plaque volume and density, some investigators
have speculated that many patients who have
extensive CAC scores may simply have higher plaque
density yet not more plaque burden, which might
actually lower CVD risk (17,18,22,23). Similarly, there
has been much discussion about endurance athletes,
such as marathon runners, whose higher CAC scores
may be driven by higher plaque density, which may
be relatively protective (24–28).
FIGURE 1 Mortality Rate Per 1,000 Person-Years for CVD, CHD, Cancer, and All-Cause Mortality by CAC Score Group
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Incidence rates increased for all-cause and cause-speciﬁc mortality with increasing CAC scores. Particularly those with CAC score $1,000 had
a 5.1, 8.0, 4.6, and 18.8 mortality rate per 1,000 person-years for CHD, CVD, cancer, and all-cause mortality, respectively. In contrast, those
with CAC scores from 400 to 99 had a 2.1, 3.6, 2.7, and 9.8 mortality rate per 1,000 person-years for CHD, CVD, cancer, and all-cause
mortality, respectively. *A version of this ﬁgure including error bars for 95% conﬁdence interval can be found in Supplemental Figure 1.
CAC ¼ coronary artery calcium; CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease.
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6However, the present study shows that those with
CAC scores $1,000 constitute a distinct population of
patients who are at a signiﬁcantly higher risk of CVD,
CHD, cancer, and all-cause mortality than those with
CAC scores 400 to 999. Furthermore, not only did
these patients have markedly higher CAC burden (CAC
area), they also had more extracoronary calcium, such
as TAC, AVC, and MVC, than patients with lower CAC.
Therefore, it appears that patients with extreme CAC
scores have a higher total burden of both coronary and
extracoronary atherosclerosis than those with just
high CAC scores (CAC sores of 400 to 999). The most
likely reason why the present data contradict those of
the prior study by Coylewright et al. (12) has to do with
statistical power. Although the analysis of the MESA
study by Coylewright et al. (12) had just 257 patients
with CAC scores $1,000 (too few to show a difference
in CHD mortality), the cohort in the present study
included 2,869 patients with CAC scores $1,000,
which is 10-fold more than the number in the MESA
cohort, with longer follow-up (12).
Guidelines from organizations such as the Amer-
ican College of Cardiology (ACC) and American Heart
Association (AHA) currently describe the highest riskgroup for coronary events and mortality as patients
with CAC scores >300 or >400 (8–11). The present
data argue that those with extensive CAC scores
($1,000) represent a distinct group of patients at the
highest risk for all-cause mortality and cardiovascular
mortality. The present analyses indicate a potential
for future guidelines to recognize asymptomatic pa-
tients with extensive Agatston scores (CAC $1,000) as
a distinct group in whom targeted and more aggres-
sive treatment should be considered.
For example, many current recommendations in
preventive cardiology include goals for LDL lowering
and blood pressure reduction, among other modiﬁable
risk factors (29–32). Speciﬁcally, a reduction of
approximately 38 mg/dl (1 mmol/l) of LDL-C has been
found to reduce the risk of cardiovascular mortality
and nonfatal infarctions by 20% to 25% (33,34); and the
newest evidence from the IMPROVE-IT (Examining
Outcomes in Subjects With Acute Coronary
Syndrome: Vytorin [Ezetimibe/Simvastatin] vs
Simvastatin [P04103] (IMProved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial;
NCT00202878), FOURIER (Further Cardiovascular
Outcomes Research With PCSK9 Inhibition in Subjects
FIGURE 2 Causes of Mortality for CAC Score 400 to 999 and CAC Score $1,000 Groups
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In both of the CAC groups, the leading cause of death was CVD (CAC scores: 400 to 999 ¼ 36.5%; CAC scores $1,000 ¼ 42.6%), followed by cancer (CAC scores of
400 to 999 ¼ 28.0%; CAC scores $1,000 ¼ 24.3%). CHD mortality, as a subset of CVD mortality, constituted 21.1% of deaths in the CAC score 400 to 999 group and
27.1% of deaths in the CAC score $1,000 group. CHF ¼ congestive heart failure; other abbreviations as in Figure 1.
TABLE 3 Hazard Ratios for All-Cause and Cause-Speciﬁc Mortality by CAC Score Group
CAC 0 Reference Group
Model 1-Unadjusted HRs
Cause of Mortality, HR (95% CI)
Agatston
Score CVD CHD Cancer All-Cause
0 Ref. Ref. Ref. Ref.
1-399 3.49 (2.85–4.27) 4.14 (3.05–5.63) 1.96 (1.70–2.26) 2.50 (2.28–2.75)
400-999 10.85 (8.63–13.64) 14.86 (10.64–20.74) 3.52 (2.88–4.30) 6.07 (5.39–6.83)
$1,000 24.23 (19.49–30.12) 36.26 (26.44–49.73) 5.87 (4.80–7.18) 11.64 (10.38–13.05)
Model 2-Fully Adjusted HRs*
Cause of Mortality, HR (95% CI)Agatston
Score CVD CHD Cancer All-Cause
0 Ref. Ref. Ref. Ref.
1-399 1.77 (1.43–2.18) 1.99 (1.45–2.74) 1.09 (0.94–1.27) 1.37 (1.24–1.52)
400-999 3.09 (2.41–3.97) 3.90 (2.72–5.59) 1.19 (0.95–1.48) 1.98 (1.73–2.25)
$1,000 5.04 (3.92–6.48) 6.79 (4.74–9.73) 1.55 (1.23–1.95) 2.89 (2.53–3.31)
CAC 400-999 Reference Group
Model 1-Unadjusted HRs*
Cause of Mortality, HR (95% CI)
Agatston
Score CVD CHD Cancer All-Cause
400-999 Ref. Ref. Ref. Ref.
$1,000 2.23 (1.84–2.70) 2.43 (1.90–3.11) 1.65 (1.31–2.09) 1.91 (1.69–2.15)
Model 2-Fully Adjusted HRs
Cause of Mortality, HR
(95% CI)Agatston
Score CVD CHD Cancer All-cause
400-999 Ref. Ref. Ref. Ref.
$1,000 1.71 (1.41–2.08) 1.84 (1.43–2.36) 1.36 (1.07–1.73) 1.51 (1.33–1.70)
*Adjusted for age, sex, hypertension, dyslipidemia, smoking, diabetes, and family history of CHD.
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; HR ¼ hazard ratio;
Ref. ¼ reference; other abbreviation as in Table 1.
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7With Elevated Risk; NCT01764633), and ODYSSEY-
OUTCOMES (ODYSSEY Outcomes: Evaluation of
Cardiovascular Outcomes After an Acute Coronary
Syndrome During Treatment With Alirocumab;
NCT01663402) clinical trials suggest that combining
statins with nonstatins, such as ezetimibe or PCSK9
inhibitors, can signiﬁcantly reduce CVD outcomes,
even in patients who are taking maximally tolerated
intensive statin therapy (35–38).
Guidelines from medical societies, particularly the
American Association of Clinical Endocrinologists
(AACE), have begun recommending very low LDL-C
goals (<55 mg/dl) in those who are at “extreme risk”
(35,39). Based on the present data, the authors argue
that many patients with CAC scores $1,000 are at
extreme risk and can be considered for the most
aggressive therapies, including nonstatin lipid-
lowering therapies such as ezetimibe or PCSK9 in-
hibitors. For example, in the FOURIER trial, which
enrolled stable secondary prevention patients for a
median of 2.2 years after their last CVD event, the
annualized cardiovascular death rate (0.77%/year) in
the placebo group was lower than the CVD mortality
rate these authors observed in asymptomatic primary
prevention patients with CAC scores $1,000 (8.0 per
1,000 patient-years, or 0.80%/year) (36). Such data
from those with CAC scores $1,000 help to blur the
lines between primary and secondary prevention (40).
In addition, prior data suggest a high risk of ischemia in
those patients (41), arguing for taking a more thorough
history to ensure that they are truly asymptomatic.
FIGURE 3 Adjusted Hazard Ratios and 95% CI for CVD, CHD, Cancer, and All-Cause Mortality by Continuous CAC Score
1
0 500 1000
CAC Score
1500 2000
3.5
3
2.5
2
1.5
Al
l C
au
se
 D
ea
th
0 500 1000
CAC Score
1500 2000
1
9
7
5
3
CV
D 
De
at
h
1
0 500 1000
95% Confidence Interval Hazard Ratio
CAC Score
1500 2000
11
9
7
5
3
CH
D 
De
at
h
0 500 1000
CAC Score
1500 2000
1
2
1.8
1.4
1.6
1.2
Ca
nc
er
 D
ea
th
Cubic splines were used to study the relationship between CAC score and mortality outcomes, with hazard ratios adjusted for age, sex, and
conventional risk factors. Knots were placed at CAC scores of 100 and 1,000. With increasing CAC score, mortality risk continues to increase
logarithmically for all-cause and cause-speciﬁc mortality, with no apparent plateau in risk. CI ¼ conﬁdence interval; other abbreviations as in
Figure 1.
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8Patients who are truly asymptomatic should be
managedwith preventative risk-reducingmedications
only.
STUDY LIMITATIONS. First, because the CAC Con-
sortium data consist of patients referred for CAC
screening, these patients may not be representative
of the general population. First, however, previous
studies indicate that the CAC Consortium contains
patients with characteristics that are generally similar
to those of participants in the Framingham Heart
Study and MESA studies (13,42). Second, data for
covariates such as diabetes, hypertension, and dys-
lipidemia relied in part on self-reports, and further-
more, these data were adjusted in analytical models
rather than reporting of actual blood pressure and
lipid proﬁles. Therefore the models used may be
subject to some residual confounding. Third, data for
race and advanced imaging characteristics was
available only from a subset of the study cohort.However, these data were missing at random relative
to CAC scores and outcomes, and therefore, the pre-
sent authors expect differential bias in analyses using
these data points. Fourth, creatinine measurements
or information on chronic kidney disease (CKD) was
not available in the population analyzed for the pre-
sent study. Thus, the present authors were unable to
adjust for kidney function in this analysis. However,
none of these patients had end-stage renal disease at
baseline, and through the review of the source pop-
ulations from which the CAC Consortium was
derived, it was expected <1% would have advanced
CKD (CKD 3B or above). Fifth, CAC scans were not
read at a central laboratory but rather at 4 different
centers as part of the clinical workﬂow. However,
the site-speciﬁc reading of CAC scores adds general-
izability to clinical practice, as these scans closely
resemble those done routinely in the community.
Sixth and ﬁnally, a key limitation is that the present
authors did not have data for the follow-up treatment
CENTRAL ILLUSTRATION Understanding Extensive CAC (CAC Score $1,000) in Primary Prevention Patients
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Primary prevention patients with extensive CAC (CAC $1,000) are unique in their burden of coronary and extra-coronary disease and in their long-term outcomes.
Those with CAC $1,000 can be found on imaging to have a dispersed pattern of calciﬁcation in their coronary artery tree (the majority with 4-vessel disease) and
diffuse extra-coronary calciﬁcation (TAC, AVC, and MVC). In addition, their annualized CVD mortality rates exceed those of high-risk secondary prevention patients
from the FOURIER trial (0.80%/year vs. 0.77%/year). AVC ¼ aortic valve calcium; CAC ¼ coronary artery calcium; CVD ¼ cardiovascular disease; MVC ¼ mitral valve
artery; TAC ¼ thoracic artery calcium.
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9of patients after they received their CAC scores.
Those with CAC scores $1,000 were most likely
treated aggressively; however, such treatment would
bias the present results to the null, making the ﬁnd-
ings even more signiﬁcant and powerful.
CONCLUSIONS
A study of the largest sample of patients with CAC
scores $1,000 yet assembled shows that patients with
extensive CAC are unique in their burden of coronaryand extracoronary disease and in their long-term
outcomes. The present data argue for consideration
of patients with CAC scores $1,000 as a distinct group
with CVD mortality greater than that of contemporary
secondary prevention trials like FOURIER.
ADDRESS FOR CORRESPONDENCE: Dr. Michael J.
Blaha, Director of Clinical Research, Ciccarone Center
for the Prevention of Heart Disease, Blalock 524D1,
600 North Wolfe Street, Baltimore, Maryland 21287.
E-mail: mblaha1@jhmi.edu.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients
with extensive CAC scores (CAC $1,000; 4.3% of our
population) have distinct imaging characteristics, with
higher area and density of CAC, nearly ubiquitous multi-
vessel disease, and characteristically diffuse extracoro-
nary calciﬁcation (TAC, MVC, and AVC). Furthermore,
they are unique in their high risk of all-cause and cause-
speciﬁc mortality, with CAC $1,000 patients showing
50% increased risk of CVD mortality compared to those
with CAC scores of 400 to 999, independent of con-
ventional CVD risk factors. Furthermore, risk continues to
climb logarithmically with higher CAC scores above
1,000, with no clear evidence of a risk plateau. Present
data show that these patients have CVD mortality greater
than that of secondary prevention trials (such as FOUR-
IER), lending them a unique risk status that may inform
intensity of preventive therapy.
TRANSLATIONAL OUTLOOK: Identiﬁcation of
asymptomatic patients with CAC scores $1,000 is
important in clinical practice, given their very high risk of
mortality. More studies comparing outcomes in
CAC $1,000 patients to routine secondary prevention
patients are needed to further inform treatment guide-
lines. In addition, future randomized controlled trials of
aggressive preventative therapies, for example, PCSK9
inhibitors and anti-inﬂammatory drugs, in patients with
CAC scores $1,000, may prove helpful to evaluate the
beneﬁts of such treatment in this unique group. Last, it
may be important to update current guidelines reﬂecting
the best practices in this distinct group of patients with
CAC scores $1,000.
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